BACKGROUND: Levels of pentosidine (representative of advanced glycation end-products) in sera of patients with rheumatoid arthritis are increased when compared with sera of other diagnoses or healthy controls. These levels have been reported to correlate with clinical indices of rheumatoid arthritis activity and with laboratory markers of inflammation. The purpose of this study was to find out if these findings pertain to other advanced glycation end-products. METHODS: We have developed two immunoassays based on new monoclonal antibodies to advanced glycation end-products. Antibody 103-E3 reacts with an unidentified antigen, formed in the reaction of proteins with ribose, while antibody 8-C1 responds to Nepsilon-(carboxyethyl)lysine. We have used these monoclonal antibodies to measure levels of advanced glycation end-products in sera of patients with rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and healthy controls. We calculated the correlations between advanced glycation end-product levels in rheumatoid arthritis sera and the Disease Activity Score 28 (DAS28), age, disease duration, CRP, anti-CCP, rheumatoid factor and treatment with corticosteroids, respectively. RESULTS: Levels of both glycation products were significantly higher in sera of patients with rheumatoid arthritis when compared with sera of patients with systemic lupus erythematosus, osteoarthritis, or the healthy controls. Neither the level of Nepsilon-(carboxyethyl)lysine nor the level of the 103-E3 antigen in rheumatoid arthritis sera correlated with the DAS28-scored rheumatoid arthritis activity. The levels of both antigens in rheumatoid arthritis sera did not correlate with age, gender, corticosteroid treatment, or levels of CRP, anti-CCP antibodies, and rheumatoid factor in sera. CONCLUSIONS: We report highly specific increases in the levels of two advanced glycation end-products in sera of patients with rheumatoid arthritis. This increase could be explained neither by rheumatoid arthritis activity nor by inflammation. We propose a working hypothesis that presumes the existence of a link between advanced glycation end-product formation and induction of autoimmunity.

Department of Medical Chemistry and Biochemistry 2nd Faculty of Medicine Charles University 5 Uvalu 84 Praha CZ 150 06 Czech Rep

Zobrazit více v PubMed

Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S. Nε-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry. 1996;35:8075–8083. doi: 10.1021/bi9530550. PubMed DOI

Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem. 1989;264:21597–21602. PubMed

Zhang Q, Ames JM, Smith RD, Baynes JW, Metz TO. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Peoteome Res. 2009;8:754–769. doi: 10.1021/pr800858h. PubMed DOI PMC

Takahashi M, Suzuki M, Kushida K, Miyamoto S, Inoue T. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Brit J Rheumatol. 1997;36:637–642. doi: 10.1093/rheumatology/36.6.637. PubMed DOI

Rodriguez-Garcia J, Requena JR, Rodriguez-Segade S. Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem. 1998;44:250–255. PubMed

Chen JR, Takahashi M, Suzuki M, Kushida K, Miyamoto S, Inoue T. Comparison of the concentration of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 1999;38:1275–1278. doi: 10.1093/rheumatology/38.12.1275. PubMed DOI

Hein GE, Köhler M, Oelzner P, Stein G, Franke S. The advanced glycation end-product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol Int. 2005;26:137–141. doi: 10.1007/s00296-004-0518-1. PubMed DOI

Šenolt L, Braun M, Vencovský J, Šedová L, Pavelka K. Advanced glycation end-product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis. Physiol Res. 2007;56:771–777. PubMed

Kageyama Y, Takahasi M, Nagafusa T, Torikai E, Nagano A. Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine in patients with rheumatoid arthritis. Mod Rheumatol. 2007;17:398–402. doi: 10.1007/s10165-007-0607-6. PubMed DOI

Kageyama Y, Takahasi M, Ichikawa T, Torikai E, Nagano A. Reduction of oxidative stress marker levels by anti-TNFα antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:73–80. PubMed

Kageyama Y, Takahasi M, Nagafusa T, Torikai E, Nagano A. Etarnecept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int. 2008;28:245–251. doi: 10.1007/s00296-007-0419-1. PubMed DOI

Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, Kurokawa K. Increased pentosidine, an advanced glycation end-product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun. 1998;244:45–49. doi: 10.1006/bbrc.1998.8203. PubMed DOI

Izuhara Y, Miyata M, Ueda Y, Suzuki D, Asahi K, Inagi R, Sakai H, Kurokawa K. A sensitive and specific ELISA for plasma pentosidine. Nephrol Dial Transplant. 1999;14:576–580. doi: 10.1093/ndt/14.3.576. PubMed DOI

Sanaka T, Funaki T, Tanaka T, Hoshi S, Niwayama J, Taitoh T, Nishimura H, Higuchi C. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. Nephron. 2002;91:64–73. doi: 10.1159/000057606. PubMed DOI

Horiuchi S, Araki N, Morino Y. Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. J Biol Chem. 1991;266:7329–7332. PubMed

Koito W, Araki T, Horiuchi S, Nagai R. Conventional antibody against Nε-(carboxymethyl)lysine (CML) shows cross-reaction to Nε-(carboxyethyl)lysine (CEL): immunochemical quantification of CML with a specific antibody. J Biochem (Tokyo) 2004;136:831–837. PubMed

Nagai R, Fujiwara Y, Mera K, Yamagata K, Sakashita M, Takeya M. Immunochemical detection of Nε-(carboxyetlyl)lysine using a specific antibody. J Immunol Met. 2008;332:112–120. doi: 10.1016/j.jim.2007.12.020. PubMed DOI

Valencia JV, Weldon SC, Quinn D, Kiers GH, DeGroot J, TeKoppele JM, Hughes TE. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem. 2004;324:68–78. doi: 10.1016/j.ab.2003.09.013. PubMed DOI

Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. Nε-(carboxyetlyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J. 1997;324:565–570. PubMed PMC

Stenger DA, Kubiniec RT, Purucker WJ, Liang H, Hui SW. Optimization of electrofusion parameters for efficient production of murine hybridomas. Hybridoma. 1988;7:505–518. doi: 10.1089/hyb.1988.7.505. PubMed DOI

Haycock JW. Polyvinylpyrrolidone as a blocking agent in immunochemical studies. Anal Biochem. 1993;208:397–399. doi: 10.1006/abio.1993.1068. PubMed DOI

Prevoo ML, van T'Hof MA, Kuper HH, van Leeuwen MA, Putte LB van De, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–48. doi: 10.1002/art.1780380107. PubMed DOI

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35:630–640. doi: 10.1002/art.1780350606. PubMed DOI

Kellgren JH, Lawrence JS. Radiological assesment of osteoarthritis. Ann Rheum Dis. 1957;16:494–501. doi: 10.1136/ard.16.4.494. PubMed DOI PMC

Misciagna G, De Michele G, Trevisan M. Non enzymatic glycated proteins in the blood and cardiovascular disease. Curr Pharm Des. 2007;13:3688–3695. doi: 10.2174/138161207783018545. PubMed DOI

Baynes JW, Thorpe SR, Murtiashaw MH. Nonenzymatic glucosylation of lysine residues in albumin. Methods Enzymol. 1984;106:88–98. full_text. PubMed

Zhang Q, Tang N, Schepmoes AA, Phillips LS, Smith RD, Metz TO. Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J Peoteome Res. 2008;7:2025–2032. doi: 10.1021/pr700763r. PubMed DOI PMC

Schleicher ED, Olgemöller B, Wiedenmann E, Gerbitz KD. Specific glycation of albumin depends on its half-life. Clin Chem. 1993;39:625–628. PubMed

Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw N, Lyons TJ, Bijlsma JWJ, Lafeber FPJG, Baynes JW, TeKoppele JT. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem. 2000;275:39027–39031. doi: 10.1074/jbc.M006700200. PubMed DOI

Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009;7 doi: 10.1186/1479-5876-7-17. PubMed DOI PMC

Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Yani SD, Hofmann N, Yan SF, Pischetsrieder M, Stern D, Schmidt AM. Nε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740–31749. doi: 10.1074/jbc.274.44.31740. PubMed DOI

van Venrooij WJ, Prujin GJM. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res Ther. 2000;2:249–251. PubMed PMC

Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Erlandsson Harris H, Ulfgren A-K, Rantapää-Dahlquist S, Eklund A, Padyukov L, Alfredsson L. the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A new model for an etiology of rheumatoid arthritis. Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54:38–46. doi: 10.1002/art.21575. PubMed DOI

Doyle HA, Mamula MJ. Posttranslational protein modifications: new flavors in the menu of autoantigens. Curr Opin Rheum. 2002;14:244–249. doi: 10.1097/00002281-200205000-00009. PubMed DOI

Doyle HA, Mamula MJ. Posttranslational modifications of self-antigens. Ann N Y Acad Sci. 2005;1050:1–9. doi: 10.1196/annals.1313.001. PubMed DOI

Atassi MZ, Casali P. Molecular mechanisms of autoimmunity. Autoimmunity. 2008;41:123–132. doi: 10.1080/08916930801929021. PubMed DOI

Eggleton P, Haigh R, Winyard PG. Consequence of neo-antigenicity of the "altered self". Rheumatology (Oxford) 2008;47:567–571. doi: 10.1093/rheumatology/ken014. PubMed DOI

Alavi A, Axford JS. Glyco-biomarkers: Potential determinants of cellular physiology and pathology. Disease Markers. 2008;25:193–205. PubMed PMC

Parekh RB, Dwek RA, Sutton BJ, Fernandez DL, Leung A, Stanworth D, Rademacher TW, Mizoguchi T, Taniguchi T, Matsuta K, Takeuchi F, Nagano Y, Miyamoto T, Kobata A. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316:452–457. doi: 10.1038/316452a0. PubMed DOI

Tomana M, Schrohenloher RE, Koopman WJ, Alarcon G, Paul WA. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum. 1988;31:333–338. doi: 10.1002/art.1780310304. PubMed DOI

Čirič D, Miloševič-Jovčič N, Ilič V, Petrovič S. A longitudinal study of the relationship between galactosylation degree of IgG and rheumatoid factor titer and avidity during long-term immunization of rabbits with BSA. Autoimmunity. 2005;38:409–416. doi: 10.1080/08916930500241785. PubMed DOI

Das H, Atsumi T, Fukushima Y, Shibuya H, Ito K, Yamada Y, Amasaki Y, Ichikava K, Amengual O, Koike T. Diagnosic value of antiagalactosyl IgG antibodies in rheumatoid arthritis. Clin Rheumatol. 2004;23:218–222. doi: 10.1007/s10067-003-0860-9. PubMed DOI

Lu MC, Hsieh SC, Lai NS, Li KJ, Wu CH, Yu CL. Comparison of anti-agalactosyl IgG antibodies, rheumatoid factors, and anti-cyclic citrullinated peptide antibodies in the differential diagnosis of rheumatoid arthritis and its mimics. Clin Exp Rheumatol. 2007;25:716–721. PubMed

Ligier S, Fortin PR, Newkirk MM. A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Br J Rheumatol. 1998;37:1307–1314. doi: 10.1093/rheumatology/37.12.1307. PubMed DOI

Lucey MD, Newkirk MM, Neville C, Lepage K, Fortin PR. Association between IgM response to IgG damaged by glyoxidation and disease activity in rheumatoid arthritis. J Rheumatol. 2000;27:319–323. PubMed

Oxidative Stress in the Developing Rat Brain due to Production of Reactive Oxygen and Nitrogen Species

Pentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritis